| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RNASE6 |
| Uniprot No | Q93091 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-150aa |
| 氨基酸序列 | WPKRLTKAHWFEIQHIQPSPLQCNRAMSGINNYTQHCKHQNTFLHDSFQNVAAVCDLLSIVCKNRRHNCHQSSKPVNMTDCRLTSGKYPQCRYSAAAQYKFFIVACDPPQKSDPPYKLVPVHLDSIL |
| 预测分子量 | 19.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RNASE6重组蛋白的3篇参考文献及其摘要概括：
1. **《Antimicrobial activity of human RNASE6 in urinary tract infections》**
- 作者：Dyer KD, et al.
- 摘要：研究报道了重组人RNASE6蛋白在体外对尿路致病性大肠杆菌的抗菌活性，揭示了其在先天免疫防御中的潜在作用。
2. **《Recombinant RNASE6 modulates macrophage polarization in chronic inflammation》**
- 作者：Spencer JD, et al.
- 摘要：通过表达纯化重组RNASE6.发现其可通过调控TLR信号通路促进巨噬细胞向抗炎表型转化，提示其在慢性炎症疾病中的治疗潜力。
3. **《Structural and functional characterization of RNASE6 variants in primate evolution》**
- 作者：Zhang J, et al.
- 摘要：分析了不同灵长类动物中重组RNASE6蛋白的序列差异，结合晶体结构数据阐明其抗菌功能在进化中的保守性与适应性变化。
(注：以上文献信息为示例性内容，实际文献需通过PubMed或学术数据库检索确认。)
**Background of RNASE6 Recombinant Protein**
RNASE6. a member of the ribonuclease A (RNase A) superfamily, is a cationic protein encoded by the *RNS6* gene in humans. It is primarily recognized for its role in innate immunity, particularly in host defense against microbial pathogens. RNASE6 exhibits potent ribonucleolytic activity, enabling it to degrade microbial RNA, thereby disrupting pathogen viability. This protein is constitutively expressed in immune cells, such as neutrophils and macrophages, and is secreted into bodily fluids, including urine and plasma. Its expression is upregulated during infections, suggesting a critical function in combating bacterial invaders, especially in the urinary tract.
Structurally, RNASE6 shares conserved catalytic motifs with other RNase A members but displays unique substrate specificity and enhanced antimicrobial properties. Recombinant RNASE6 is produced via genetic engineering, typically using prokaryotic (e.g., *E. coli*) or eukaryotic expression systems, followed by purification techniques like affinity chromatography. The recombinant form retains enzymatic and antimicrobial activities, making it a valuable tool for studying innate immune responses and pathogen interactions.
Research highlights its broad-spectrum antibacterial effects against pathogens like *E. coli* and *Staphylococcus aureus*, even under physiological conditions. Beyond direct microbicidal activity, RNASE6 may modulate immune signaling pathways, enhancing phagocytosis or cytokine production. These dual mechanisms position it as a potential therapeutic candidate for antibiotic-resistant infections. Additionally, recombinant RNASE6 aids in elucidating structure-function relationships within the RNase family and exploring its role in non-infectious diseases, such as cancer or chronic inflammation.
In summary, RNASE6 recombinant protein bridges fundamental immunology and translational research, offering insights into antimicrobial defense and therapeutic innovation.
×
